Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375279 | 0.89 | CES2 (0.52) | CYP2A6CES2CES1ALOX15TSHR | |
| SCHEMBL727139 | 0.89 | CES2 (0.52) | CYP2A6CES2CES1ALOX15TSHR | |
| SCHEMBL8775402 | 0.84 | LCK (0.48) | CYP2A6CES2CES1ALOX15TSHR | |
| SCHEMBL743388 | 0.83 | TSHR (0.60) | CYP2A6ALOX15TSHRMEN1KMT2A | |
| SCHEMBL1681902 | 0.81 | CES2 (0.50) | CYP2A6CES2CES1ALOX15TSHR | |
| SCHEMBL8967726 | 0.81 | SRD5A2 (0.57) | CYP2A6CES2CES1ALOX15TSHR | |
| SCHEMBL19554196 | 0.81 | LCK (0.62) | CYP2A6MEN1KMT2APLAULCK | |
| SCHEMBL11662765 | 0.81 | CYP2A6 (0.55) | CYP2A6CES2CES1MAOBRAB9A | |
| SCHEMBL7358277 | 0.80 | KDM4E (0.57) | CES2CES1ALOX15TSHRMEN1 | |
| SCHEMBL1225 | 0.80 | CES2 (0.68) | CES2CES1ALOX15RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888469-B1 | OPTICALLY ANISOTROPIC SPINNING SOLUTION COMPRISING A MIXTURE OF P-ARAMID AND ALIPHATIC POLYAMIDE, AND FIBRES TO BE MADE THEREFROM | TEIJIN TWARON BV (NL) | 2002-12-11 | — | — | EP | claimed |
| US-5962627-A | MECHANICAL PROPERTIES; ADHESIVES | AKZO NOBEL N.V. (NL) | 1999-10-05 | — | — | US | claimed |
| EP-0888469-A1 | OPTICALLY ANISOTROPIC SPINNING SOLUTION COMPRISING A MIXTURE OF P-ARAMID AND ALIPHATIC POLYAMIDE, AND FIBRES TO BE MADE THEREFROM | Akzo Nobel N.V. (NL) | 1999-01-07 | — | — | EP | claimed |
| WO-1997033022-A1 | OPTICALLY ANISOTROPIC SPINNING SOLUTION COMPRISING A MIXTURE OF P-ARAMID AND ALIPHATIC POLYAMIDE, AND FIBRES TO BE MADE THEREFROM | AKZO NOBEL N.V. (NL) | 1997-09-12 | — | — | WO | claimed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2017192304-A1 | ARYLCARBOXAMIDES AND USES THEREOF | INCEPTION 1, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-0339987-B1 | Liquid crystal compounds having naphthalene nucleus | SHOWA SHELL SEKIYU (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-4973738-A | Liquid crystal compounds having naphthalene nucleus | SHOWA SHELL SEKIYU K.K. (JP) | 1990-11-27 | — | — | US | disclosed |
| EP-0339987-A2 | Liquid crystal compounds having naphthalene nucleus | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4769373-A | Anti-arrhythmic azabicyclic compounds | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | CYP2A6 672/4885CES2 819/4885CES1 416/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CYP2A6 672/4885CES2 819/4885CES1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.